Meijing AI News, September 17, Saili Medical(603716.SH) announced plans to increase capital by 42.7429 million yuan in its subsidiary, Wuhan Huajiyuan Biotechnology Development Co., Ltd. Upon completion of the capital increase, the company's stake in Wuhan Huajiyuan will increase to 41%. Concurrently, the company's actual controller, Wen Wei, plans to acquire a 10% stake in Wuhan Huajiyuan shareholder Sun Danping for 27.2 million yuan, at a post-capital valuation of 272 million yuan. The company and its actual controller, Wen Wei, will contribute a total of 69.9429 million yuan in this transaction. The target company will be consolidated as a controlled subsidiary of the company in 2026. All parties agreed to actively advance the various phases of clinical trials for the target company's therapeutic antihypertensive vaccine (HJY-ATRQβ-001) project and work together to develop the target company's business. Upon completion of the capital increase, all parties pledged to actively conduct research and development, testing, and clinical validation, striving to complete Phase I and Phase IIa clinical trials of the therapeutic antihypertensive vaccine (HJY-ATRQβ-001) within two years, followed by Phase IIb clinical trials.

https://finance.eastmoney.com/a/202509173516161581.html